Brean Capitals

Pernix Therapeutics Holdings Inc (NASDAQ: PTX) reported its 2Q revenue short of expectations. Brean Capitals’ Difei Yang downgraded the rating on the company from Buy to Hold, expressing concern regarding the unclear path to sustainable revenue growth and profitability. Revenue Miss...